Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 181, doi. 10.3233/KCA-210128
- By:
- Publication type:
- Article
Works matching IS 24684562 AND DT 2021 AND VI 5 AND IP 4
Results: 6
1
2
Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 167, doi. 10.3233/KCA-210126
- By:
- Publication type:
- Article
3
Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 199, doi. 10.3233/KCA-210129
- By:
- Publication type:
- Article
4
Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 189, doi. 10.3233/KCA-210127
- By:
- Publication type:
- Article
5
Clinical Trials Corner: Reimagining RADICAL.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 219, doi. 10.3233/KCA-210002
- By:
- Publication type:
- Article
6
First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials.
- Published in:
- Kidney Cancer (2468-4562), 2021, v. 5, n. 4, p. 207, doi. 10.3233/KCA-210123
- By:
- Publication type:
- Article